Cargando…

Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus

PURPOSE: To assess the association of type 2 diabetes mellitus (T2DM) and insulin glargine treatment with bone mineral density (BMD) in Chinese people. METHODS: This retrospective study included 50 subjects with T2DM: 25 received oral glucose-lowering medication (ORL group), and 25 received oral glu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Dan, Bai, Jing-Jie, Yao, Jun-Jie, Wang, Yong-Bo, Chen, Tong, Xing, Qian, Bai, Ran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092849/ https://www.ncbi.nlm.nih.gov/pubmed/33953588 http://dx.doi.org/10.2147/DMSO.S302627

Ejemplares similares

The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus
por: Akyay, Ozlem Zeynep, et al.
Publicado: (2023)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
por: Eledrisi, Mohsen, et al.
Publicado: (2018)

Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

The metabolic score of insulin resistance is positively correlated with bone mineral density in postmenopausal patients with type 2 diabetes mellitus
por: Gu, Peng, et al.
Publicado: (2023)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Bone mineral density evaluation of patients with type 2 diabetes mellitus
por: Adil, Camli, et al.
Publicado: (2015)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Vitamin D is Positively Associated with Bone Mineral Density Muscle Mass and Negatively with Insulin Resistance in Senile Diabetes Mellitus
por: Gao, Yan, et al.
Publicado: (2022)

The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus
por: Wang, Jie, et al.
Publicado: (2019)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

Increased bone mineral density in postmenopausal women with type 2 diabetes mellitus
por: Hadzibegovic, Irzal, et al.
Publicado: (2008)

Prolactin is associated with bone mineral density in subjects with type 2 diabetes mellitus
por: Chen, Jia, et al.
Publicado: (2022)

Effects of different doses of metformin on bone mineral density and bone metabolism in elderly male patients with type 2 diabetes mellitus
por: Wang, Lin-Xia, et al.
Publicado: (2020)

Association between renal function and bone mineral density in patients with type 2 diabetes mellitus
por: Ye, Yangli, et al.
Publicado: (2023)

Association of body composition with bone mineral density and fractures in Chinese male type 2 diabetes mellitus
por: Meng, Chuchen, et al.
Publicado: (2022)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Relation between the insulin lowering rate and changes in bone mineral density: Analysis among subtypes of type 1 diabetes mellitus
por: Suzuki, Masaki, et al.
Publicado: (2022)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value
por: Clissold, Rhian, et al.
Publicado: (2007)

Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
por: Joseph, Joshua J, et al.
Publicado: (2015)

Successful Insulin Glargine Treatment in Two Pet Guinea Pigs with Suspected Type 1 Diabetes Mellitus
por: Kreilmeier-Berger, Theresa, et al.
Publicado: (2021)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Bone Mineral Density in Diabetes Mellitus Foot Patients for Prediction of Diabetic Neuropathic Osteoarthropathic Fracture
por: Cho, Jae-Ho, et al.
Publicado: (2020)

A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus
por: Rostami, Parastoo, et al.
Publicado: (2014)

Association between serum levels of bone turnover markers and bone mineral density in men and women with type 2 diabetes mellitus
por: Zhao, Chenhe, et al.
Publicado: (2019)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Nerve conduction velocity is independently associated with bone mineral density in type 2 diabetes mellitus
por: Chen, Xiao-jing, et al.
Publicado: (2023)

Association Between Coronary Artery Calcium Score and Bone Mineral Density in Type 2 Diabetes Mellitus with Different Visceral Fat Area
por: Yang, Ying, et al.
Publicado: (2022)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
por: Shafie, Asrul Akmal, et al.
Publicado: (2020)

A Study of Bone Mineral Density and Its Determinants in Type 1 Diabetes Mellitus
por: Joshi, Ameya, et al.
Publicado: (2013)

Effects of the Rate of Impaired Insulin Secretion on Bone Mineral Density in Type 1 Diabetes
por: Suzuki, Masaki, et al.
Publicado: (2021)

Evaluation of bone mineral density in patients with gestational diabetes mellitus by ultrasonic bone mineral density measurement combined with Vitamin-D deficiency and analysis of influencing factors
por: Han, Lulu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9dnctus52ecqk8rqpj5j9nuaja